PC-1 Nucleoside Triphosphate Pyrophosphohydrolase Deficiency in Idiopathic Infantile Arterial Calcification-Reference-Cited by-同舟云学术

PC-1 Nucleoside Triphosphate Pyrophosphohydrolase Deficiency in Idiopathic Infantile Arterial Calcification

Published:2001-02 Issue:2 Volume:158 Page:543-554
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Rutsch Frank,Vaingankar Sucheta,Johnson Kristen,Goldfine Ira,Maddux Betty,Schauerte Petra,Kalhoff Hermann,Sano Kimihiko,Boisvert William A.,Superti-Furga Andrea,Terkeltaub Robert

Funder

Ministry of Education, Culture, Sports, Science and Technology

National Institutes of Health

U.S. Department of Veterans Affairs

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Arthritis Foundation

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference34 articles.

1. Molecular determinants of arterial calcification;Schinke;Ann Med,1998

2. Extracellular matrix calcification: where is the action?;Schinke;Nat Genet,1999

3. Natural history of calcium deposits in atherosclerosis progression and regression;Stary;Zeitschrift fur Kardiologie,2000

4. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis;Bini;Arterioscler Thromb Vasc Biol,1999

5. Idiopathic infantile arterial calcification: a case report and review of the literature;Maayan;Eur J Pediatr,1984

Cited by 266 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelets isolation and ectonucleotidase assay: Revealing functional aspects of the communication between the vasculature and the immune system;Journal of Immunological Methods;2024-10

2. Regulation of TGF-β1-induced fibroblast differentiation of human periodontal ligament stem cells through the mutually antagonistic action of ectonucleotide pyrophosphatase/phosphodiesterase 1 and 2;Frontiers in Cell and Developmental Biology;2024-09-03

3. Quantitative correlation of ENPP1 pathogenic variants with disease phenotype;Bone;2024-09

4. Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience;Journal of Nephrology;2024-08-20

5. Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics;Clinical Pharmacology & Therapeutics;2024-07-22